Literature DB >> 11992275

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

Akihiko Saitoh1, Karen Hsia, Terence Fenton, Christine A Powell, Cindy Christopherson, Courtney V Fletcher, Stuart E Starr, Stephen A Spector.   

Abstract

Human immunodeficiency virus (HIV) type 1 DNA in peripheral blood mononuclear cells (PBMC) was quantified in 31 children who received efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors for > or =2 years and in whom undetectable plasma HIV-1 RNA levels (< 50 copies/mL) were sustained, to determine the usefulness of HIV-1 DNA as a marker of virus suppression. The median baseline HIV-1 DNA level was 750 copies/10(6) PBMC. After initiation of highly active antiretroviral therapy (HAART), HIV-1 DNA levels decreased gradually, reaching a plateau from week 80 through week 104 (median HIV-1 DNA level, 263 copies/10(6) PBMC). Children who had plasma HIV-1 RNA levels < 50 copies/mL after receiving HAART for 8 weeks (n=16) had persistently lower quantities of intracellular HIV-1 DNA than children whose HIV-1 RNA levels reached < 50 copies/mL after 8 weeks of HAART (n=15). The median half-life for intracellular HIV-1 DNA was 60 weeks. Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992275     DOI: 10.1086/340614

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy.

Authors:  Akihiko Saitoh; Kumud K Singh; Sharsti Sandall; Christine A Powell; Terrence Fenton; Courtney V Fletcher; Karen Hsia; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

2.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

3.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Authors:  Priyanka Uprety; Ellen G Chadwick; Kaitlin Rainwater-Lovett; Carrie Ziemniak; Katherine Luzuriaga; Edmund V Capparelli; Gayane Yenokyan; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2015-08-13       Impact factor: 9.079

4.  A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.

Authors:  Sonia Mediouni; Jennifer D Watkins; Michel Pierres; Angélique Bole; Erwann P Loret; Gilbert Baillat
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 5.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.

Authors:  Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

7.  Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.

Authors:  Akihiko Saitoh; Terence Fenton; Carmelita Alvero; Courtney V Fletcher; Stephen A Spector
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

8.  Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection.

Authors:  Priyanka Uprety; Kunjal Patel; Brad Karalius; Carrie Ziemniak; Ya Hui Chen; Sean S Brummel; Suzanne Siminski; Russell B Van Dyke; George R Seage; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

9.  Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Authors:  Dai Watanabe; Shiro Ibe; Tomoko Uehira; Rumi Minami; Atsushi Sasakawa; Keishiro Yajima; Hitoshi Yonemoto; Hiroki Bando; Yoshihiko Ogawa; Tomohiro Taniguchi; Daisuke Kasai; Yasuharu Nishida; Masahiro Yamamoto; Tsuguhiro Kaneda; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2011-05-24       Impact factor: 3.090

10.  Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR.

Authors:  Benoît Kabamba-Mukadi; Philippe Henrivaux; Jean Ruelle; Nicole Delferrière; Monique Bodéus; Patrick Goubau
Journal:  BMC Infect Dis       Date:  2005-03-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.